Changes in Hong Kong stocks | CRO concept stocks had the highest gains. Recently, a number of overseas MNCs and CXOs disclosed interim earnings reports and raised their annual guidelines

The Zhitong Finance App learned that CRO concept stocks had the highest gains. As of press release, Yao Ming Kangde (02359) rose 11.05% to HK$180.9; Kingsley Biotech (01548) rose 10.18% to HK$17.96; Gloria Ying (06821) rose 7.71% to HK$117.4; and Pharmaceutical Biotech (02269) rose 3.92% to HK$40.34.

According to the news, Yao Ming Kangde announced that in the first half of the year, the company achieved operating income of 28.897 billion yuan, an increase of 38.93% over the previous year; net profit to mother was 11.08 billion yuan, an increase of 29.43% over the previous year. At the same time, the company comprehensively raised its 2026 annual results guide. The company's overall revenue is expected to increase from 51.3 billion yuan to 53 billion yuan to 58.5 billion yuan in 2026, and the year-on-year growth rate of continuing business revenue will increase from 18%-22% to 35%-39%.

It is worth noting that a number of overseas MNCs and CXOs have recently disclosed their earnings reports and raised their annual guidelines. Zhongtai Securities said that the demand side is gradually improving, the procyclical repair logic continues to be interpreted, and the Q2 performance is expected to continue to be impressive. With the marginal improvement of the overseas Biotech financing environment, the continued implementation of BD transactions for innovative drugs in China, and the gradual advancement of commercialization projects, the order side of the industry is expected to recover.